Riskpilot← Back to searchSign inGet full accessAGILERA PHARMA AS
ASActiveOrg 928041069Instituttveien 18, 2007 KjellerManufacture of pharmaceutical preparations · NACE 2120Est. 2021136 employees
Revenue 2024
NOK 357,6M
+23% vs 2023
EBITDA margin
-6.6%
-321% vs 2023
Equity ratio
10.1%
Financial strength
Net profit 2024
NOK -34,8M
-318% vs 2023
| Revenue | NOK 357,6M | +23% |
| EBITDA | NOK -23,8M | -321% |
| Net profit | NOK -34,8M | -318% |
| Total assets | NOK 149,2M | -5% |
| Equity | NOK 15M | -70% |
| Employees | 136 | — |
Legal name
AGILERA PHARMA AS
Org number
928041069
Legal form
Aksjeselskap
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
1. desember 2021
Share capital
NOK 4 530 000
Employees
136 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder og ett styremedlem i fellesskap.
Company purpose
Drive forskning, utvikling og produksjon av nye løsninger for medisin ved bruk av radioaktive kilder, samt andre aktiviteter som står i forbindelse hermed, herunder samarbeid med, deltakelse og eierskap i andre selskaper.
Address
Instituttveien 18, 2007 Kjeller
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | 0 | 290 816 | 357 641 |
| Staff expenses | −0 | −117 281 | −104 955 |
| EBITDA | −1 | −5 652 | −23 773 |
| Depreciation & amort. | −0 | −4 410 | −5 219 |
| EBIT | −1 | −10 062 | −28 992 |
| Net financials | 0 | −555 | −3 460 |
| Profit before tax | −1 | −10 617 | −32 452 |
| Tax | −0 | −2 298 | 2 298 |
| Net profit | −1 | −8 319 | −34 750 |
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Total assets | 23 | 157 781 | 149 225 |
| Equity | 23 | 49 772 | 15 022 |
| Long-term debt | 0 | 0 | 45 000 |
| Short-term debt | 0 | 108 009 | 89 203 |
| Total debt | 0 | 108 009 | 134 203 |
EBITDA margin
-6.6%
This company
15.8%
Market median
-142% vs market
20222024
Equity ratio
10.1%
This company
38.2%
Market median
-74% vs market
20222024
Return on equity
-231.3%
This company
18.4%
Market median
-1357% vs market
20222024
Net profit margin
-9.7%
This company
8.1%
Market median
-220% vs market
20222024
Asset turnover
2.40×
This company
1.12×
Market median
+114% vs market
20222024
Debt / equity
8.93×
This company
0.62×
Market median
-1340% vs market
20222024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2021-11-07 – 2022-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
EF Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
TL Deputy Member | Deputy Member | 2021 | — | — |
IL Deputy Member | Deputy Member | 2025 | — | — |
LH Deputy Member | Deputy Member | 2023 | — | — |
TN Deputy Member | Deputy Member | 2021 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2023 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2021 | — | — | |
JD | Board of Directors | 2021 | — | — |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2024 | — | — | |
| Chairman | 2021 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Ife Holding As | Company | 100.0% | 100.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Institutt For Energiteknikk Sti
AGILERA PHARMA AS Board members of AGILERA PHARMA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Erik Flatmark | Chief Executive Officer | 0 companies |
| Terje Lyseng | Deputy Member | 0 companies |
| Inger Lill Skuland | Deputy Member | 0 companies |
| Line Holmvaag | Deputy Member | 0 companies |
| Terje Nordland Johnsen | Deputy Member | 0 companies |
| Nils Morten Huseby | Chairman | 0 companies |
| Camilla Tveiten Engeland | Board of Directors | 0 companies |
| Silje Aspholm Hole | Board of Directors | 0 companies |
| Sven Sigfrid Ordeus | Board of Directors | 0 companies |
| Jo Døhl | Board of Directors | 0 companies |
| Atle Valseth | Board of Directors | 0 companies |
| Katrine Trovik | Board of Directors | 0 companies |
| Elisabeth Strålberg | Board of Directors | 0 companies |
| Olav Fjell | Chairman | 0 companies |
| Thomas Møen Halvorsen | Board of Directors | 0 companies |
| Ingvill Heskestad Mykland | Board of Directors | 0 companies |
| Josefine Helene Krogh Selj | Board of Directors | 0 companies |
| Anne Elisabeth Laingen | Board of Directors | 0 companies |
| Marinus Isaac Hoffmann | Board of Directors | 0 companies |